Exact Sciences (EXAS) Tops Q4 EPS by 6c, Maintains Cologuard Outlook

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.

2016 Outlook

The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between $90-100 million in revenue. This represents a greater than 130-percent year-over-year increase in the number of Cologuard tests completed and revenue growth of approximately 128 to 154 percent from 2015.

"As commercial coverage expands, the Cologuard ordering process is streamlined and our sales and marketing efforts become increasingly impactful, we believe that adoption will increase at a meaningful rate during the year ahead," Mr. Conroy said.

The company's guidance for revenue and completed tests are forward-looking statements. They are subject to various risks and uncertainties that could cause the company's actual results to differ materially from the anticipated targets. The anticipated targets are not predictions of the company's actual performance. See the cautionary information about forward-looking statements in the "Safe-Harbor Statement" section of this press release.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Nvidia pitches Vera CPU to Chinese clients with August delivery target